ProCE Banner Activity


Advances in Immune Checkpoint Inhibitor Therapy for Patients with Non-Small-Cell Lung Cancer: Applications to Clinical Practice

PCE On Demand Live Presentation

Immune checkpoint inhibitors (ICIs) are recommended for various patients with non-small-cell lung cancer (NSCLC). Healthcare professionals (HCPs) must be familiar with current expert recommendations for use of ICIs as results of biomarker testing, and PD-L1 levels can influence choice of therapy. Once ICIs are used, HCPs need to be aware of the potential for immune-related adverse events (irAEs). In this video lecture, an expert discusses strategies for optimizing ICIs in advanced NSCLC including individualizing therapy decisions and managing adverse events

Nurse Practitioners: 1.00 Nursing contact hours, includes 1.00 hour of pharmacotherapy credit

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Released: December 27, 2022

Expiration: December 26, 2023

No longer available for credit.
Begin Activity



Marianne Davies

Marianne Davies, DNP, ACNP, FAAN

Associate Professor
Yale School of Nursing
Senior Advanced Practice Nurse
Smilow Cancer Hospital at
Yale New Haven
Yale Comprehensive Cancer Center
New Haven, Connecticut

Kathleen Madden

Kathleen Madden, MSN, ANP-BC, AOCNP

Melanoma Program
NYU Langone Perlmutter Cancer Center
New York, NY

Provided by

ProCE Banner


This activity is supported by an educational grant from

Regeneron Pharmaceuticals, Inc

Target Audience

Oncology NPs, PAs, and nurses

Learning Objectives

After completing this activity, participants should be better able to:

  • Formulate evidence-based approaches for the use of immune checkpoint inhibitors (ICIs) for patients with advanced non-small-cell lung cancer (NSCLC)

  • Use recommended strategies for identifying and managing immune-related adverse events in patients treated with ICIs 

  • Integrate patient education and feedback to optimize patient experiences during treatment and survivorship


All faculty and planners participating in continuing education activities sponsored by Partners for Advancing Clinical Education (PACE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PACE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.

Marianne Davies DNP, ACNP, has no relevant financial relationships to disclose.

Kathleen Madden, MSN: consultant/advisor/speaker: Novartis.

Beth Sandy, MSN, CRNP: speaker: Amgen, AstraZeneca, Janssen, Jazz, Merck, Takeda.

The planners and content peer reviewers from Partners for Advancing Clinical Education and Practicing Clinicians Exchange, do not have any relevant financial relationships to disclose, except Beth Sandy, MSN, CRNP as listed above.

Instructions for Credit

Learners wishing to earn CE/CME credit must: 

  1. View the content in its entirety
  2. Relate the content material to the learning objectives 
  3. Complete evaluation form 

The estimated time to complete this activity is 1.00 hour.

Release date: December 27, 2022
Expiration date: December 26, 2023


This program has been made available online.


The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Partners for Advancing Clinical Education, Practicing Clinicians Exchange, or any educational supporter.


Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.


ANCC Credit Designation
Nursing contact hours: 1.00, which includes 1.00 hour of pharmacology credit


AAPA Credit Designation
Joint AccreditationPartners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until December 26, 2023. PAs should only claim credit commensurate with the extent of their participation.


IPCE Credit Designation
IPCEThis activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.